Lung clinical trials

Drug combo before surgery for EGFR-mutated lung cancer

This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.

Study of the Disease Process of Lymphangioleiomyomatosis

PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer

Glowing dye to help surgeons see lung cancer during surgery

This trial tests a dye that makes lung cancer cells glow during surgery, helping surgeons remove more of the tumor. It's for people who are already scheduled for lung cancer surgery.

Study of ABBV-706 vs standard care for advanced small cell lung cancer

This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.

AQUA07 for ALK-positive lung cancer

This trial tests a new drug called AQUA07 for patients with ALK-positive lung cancer that has spread or cannot be removed with surgery. You must have already tried at least one other ALK-targeting drug (but not just crizotinib alone) to be eligible.

New drug combo for stage 4 lung cancer

This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.

Experimental drug ST-001 nanoFenretinide for small cell lung cancer

This phase 1 trial tests an experimental drug called ST-001 nanoFenretinide for people with small cell lung cancer that has returned or not responded to standard chemotherapy. The drug is a newer form of fenretinide, which is related to vitamin A, and may work differently to attack cancer cells.

Testing sevabertinib for advanced HER2-mutated lung cancer

This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.

Lung ultrasound for surfactant decision in premature babies

This trial uses a lung ultrasound score, a type of ultrasound, to decide when to give surfactant (a medicine that helps lungs work) to premature babies born between 27 and 35 weeks of pregnancy. It aims to reduce the need for more breathing support and avoid side effects.

PET scan tracer to find lung or pancreas radiation injury

This Phase 2 study tests a special PET scan tracer to help doctors spot tissue damage after radiation treatment in people with certain lung or pancreatic cancers. The goal is to improve detection and planning around chemoradiation and surgery.

Study of BEBT-109 for lung cancer with EGFR exon 20 insertion mutation

This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.

BMS-986525 for Relapsed Small Cell Lung Cancer

This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.

Video-guided placement of breathing tube for chest surgery

This trial compares two ways of placing a breathing tube for lung surgery. It tests whether using a video to guide the tube placement works better than the standard method. If you are having keyhole chest surgery that needs one lung collapsed, this study may help improve your care.

Personalized radiotherapy for lung, brain, sarcoma, or head and neck cancers

This trial tests whether giving personalized radiotherapy alongside standard treatments can better control several types of cancer: small cell lung cancer, brain metastases, soft tissue sarcoma, and head and neck cancer. It aims to see if this approach helps patients live longer without their cancer growing or coming back.

Acupoint patches for nausea in lung cancer chemo

This study tests whether acupoint patches can reduce nausea and vomiting caused by chemotherapy in people with lung cancer. Acupoints are specific spots on the body used in traditional Chinese medicine.

Cemiplimab and dupilumab before lung cancer surgery

This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.

Prevention and early detection for people at high cancer risk

This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.

Calderasib plus other treatments for advanced non-small cell lung cancer

This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.

Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer

This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.

Testing a new drug combo for advanced lung cancer

This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.

Study of gilteritinib for advanced ALK-positive lung cancer

This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.

Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy

This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.

Adjuvant vaccine plus immunotherapy for high-risk early lung cancer

This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.